Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Investigational Agents for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)
This study is a rolling arm study of pembrolizumab in combination with investigational agents
in participants with anti-programmed cell death 1 (PD-1)/ programmed cell death ligand 1
(PD-L1) refractory ES-SCLC in need of second-line treatment. This study will have 2 parts: an
initial safety lead-in to determine safety and tolerability for experimental combinations of
investigational agents without an established recommended phase 2 dose (RP2D) followed by an
Investigational agents will initiate directly in or be added to the efficacy evaluation after
an initial evaluation of safety and tolerability of the investigational agent has been
completed in a separate study or in the safety lead-in of this study. If an RP2D for a
combination being evaluated in the safety lead-in is established from another study, then the
efficacy evaluation may begin at the determined RP2D.
There will be no hypothesis testing in this study.
Small Cell Lung Cancer,
small cell carcinoma,
small cell carcinoma of the lung
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.